查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085021

抗肥胖處方藥市場：依藥物類別、劑型、治療方法、應用、最終用戶和分銷管道分類－2026-2032年全球市場預測

Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗肥胖處方藥市場將成長至 127.7 億美元，複合年成長率為 8.40%。

主要市場統計數據
基準年 2025 72.5億美元
預計年份：2026年 78.4億美元
預測年份 2032 127.7億美元
複合年成長率 (%) 8.40%

抗肥胖處方藥正從單純的減重輔助藥物轉變為治療慢性體重問題和降低心血管代謝風險的主要療法。包括GLP-1受體促效劑和GIP/GLP-1受體雙重促效劑在內的腸促胰素類藥物，在大規模臨床試驗計畫的支持下，正在重塑市場格局。這些試驗項目證實了此類藥物能夠顯著減輕體重並改善代謝指標。

這些藥物的需求量龐大，且有數據支持。世界衛生組織（世衛組織）的數據顯示，2022年全球有超過10億人肥胖，其中超過8.9億人為成年人，另有25億成年人超重。在醫學領域，由於肥胖與第2型糖尿病、心血管疾病、睡眠呼吸中止症、脂肪肝和肌肉骨骼疾病密切相關，處方箋減肥藥正日益被視為一種長期醫療干預手段，而不僅僅是一種美容療法。

市場狀況的變革性變化

市場模式正從傳統的食慾抑制劑和吸收抑制劑轉向療效較佳的荷爾蒙療法。在大型STEP試驗中，2.4毫克Semaglutide平均減重約15%；而在大型SURMOUNT試驗中，替澤帕肽使患者減重超過20%，為肥胖症藥物治療樹立了新的標竿。

人工智慧的累積影響

人工智慧 (AI) 正在對抗肥胖藥物的發現、臨床開發、生產和商業化等各個階段產生累積影響。 AI 驅動的標靶發現、分子建模、研究中心選擇和臨床實驗分層有助於申辦方識別有效應答者特徵、最佳化試驗設計，並提高技術和監管成功的機率。

對關鍵區域的洞察

北美仍然是抗肥胖處方藥商業化程度最高的地區，其中美國處於領先地位。 FDA的批准、專科醫生的處方、廣泛的臨床認知以及雇主就醫療保險覆蓋範圍進行的討論，都在加速這些藥物的普及。加拿大的臨床關注度也不斷提高，但報銷規則、處方藥清單規定以及各省的准入途徑都在影響著這些藥物的使用速度。

關鍵群體特定見解

七國集團（G7）正在塑造全球趨勢，其影響領域包括證據標準、醫保報銷討論、心血管結局數據、肥胖症治療臨床指南以及對高價抗肥胖處方藥的預期。儘管歐盟透過區域核准流程建立了統一的法規結構，但各國在藥品准入方面的決策仍然分散，因此，國家層級的衛生技術評估、預算影響評估以及與支付方的談判對於藥品市場准入至關重要。

主要國家的概況

美國是GLP-1和雙重腸促胰島素類抗肥胖藥物的主要市場，這得益於FDA的批准、較高的臨床認可度、專科醫生和基層醫療醫生的處方以及強勁的患者需求，但同時也受到支付方控制、除外條款、預先核准以及自付費用等因素的限制。在加拿大，由專科醫生主導的推廣和基於指南的醫療保健正在穩步推進。同時，墨西哥和巴西的肥胖盛行率很高，但兩國的報銷體系存在差異，私人需求不斷成長，人們越來越認知到肥胖是一種需要醫療干預的慢性疾病。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床證據，這些證據不僅限於減重，還包括心血管結局、糖尿病預防、睡眠呼吸中止症、腎臟結局、肝臟健康、生活品質、安全性以及治療依從率等方面的數據。醫療保健系統在權衡慢性治療的成本與長期降低肥胖相關併發症的益處時，必須建立針對保險公司量身定做的證據包。

調查方法

本執行摘要基於對已驗證的公共領域證據的結構化審查，包括來自 FDA 和 EMA 的監管批准和處方標籤、臨床試驗註冊資訊、同行檢驗的臨床試驗文章、世界衛生組織 (WHO) 肥胖統計數據、國家公共衛生資訊來源、治療指南以及公開可用的臨床進展更新。

結論

抗肥胖處方藥正進入一個新階段，其特徵是高效的腸促胰素療法、不斷擴大的臨床證據，以及人們日益認知到肥胖是一種需要醫療管理的慢性疾病。該領域不再局限於減肥，而是與心血管代謝風險管理、預防合併症以及在醫療保健系統中的長期價值密切相關。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗肥胖處方藥市場：依藥物類別分類

  • GLP-1促效劑
    • Liraglutide
    • Semaglutide
  • 西托美拉諾胜肽
  • 奧利司他
  • 蒂爾澤帕蒂德

第8章：抗肥胖處方藥市場：以劑型分類

  • 注射藥物
  • 口服藥物
    • 膠囊
    • 藥片

第9章：抗肥胖處方藥市場：依治療類型分類

  • 單藥治療
  • 聯合治療

第10章：抗肥胖處方藥市場：依應用領域分類

  • 中度肥胖/過重的管理
  • 兒童肥胖症的管理
  • 用於精準肥胖症的治療

第11章：抗肥胖處方藥市場：以最終用戶分類

  • 門診部
  • 居家醫療
  • 醫院
  • 專科診所
    • 內分泌診所
    • 一般診所
    • 減重診所

第12章：抗肥胖處方藥市場：依通路分類

  • 離線
  • 線上

第13章：抗肥胖處方藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗肥胖處方藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗肥胖處方藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alizyme Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • BioCon Limited
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hangzhou Sciwind Biosciences Co., Ltd.
  • Hanmi Pharm.Co., Ltd.
  • HK inno.N Corporation
  • Innovent Biologics, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Reddy's Laboratories Limited
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Company Limited
  • Verdiva Pharma Inc.
  • Viking Therapeutics
  • Vivus LLC
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market is projected to grow by USD 12.77 billion at a CAGR of 8.40% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.25 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 12.77 billion
CAGR (%) 8.40%

Anti-obesity prescription drugs have moved from adjunctive weight-loss aids to core therapies for chronic weight management and cardiometabolic risk reduction. The landscape is being reshaped by incretin-based medicines, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, supported by large clinical programs showing clinically meaningful weight reduction and improvements in metabolic markers.

The demand backdrop is substantial and data-backed: the World Health Organization reported that, in 2022, more than 1 billion people were living with obesity, including over 890 million adults, while 2.5 billion adults were overweight. As health systems connect obesity with type 2 diabetes, cardiovascular disease, sleep apnea, fatty liver disease, and musculoskeletal disorders, prescription anti-obesity medications are increasingly positioned as long-term medical interventions rather than cosmetic treatments.

Transformative Shifts in the Market Landscape

The landscape is shifting from older appetite suppressants and absorption inhibitors toward hormone-based therapies with stronger efficacy profiles. Semaglutide 2.4 mg demonstrated about 15% mean body-weight reduction in pivotal STEP trials, while tirzepatide produced weight reductions exceeding 20% in major SURMOUNT studies, establishing new benchmarks for obesity pharmacotherapy.

At the same time, payers, regulators, employers, and healthcare providers are reassessing access because obesity treatment creates near-term pharmacy cost pressure alongside potential long-term reductions in cardiometabolic complications. Competitive strategy is now centered on differentiation in efficacy, tolerability, dosing convenience, cardiovascular outcomes, oral formulations, manufacturing scale, and real-world evidence that supports reimbursement for chronic use.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across anti-obesity drug discovery, clinical development, manufacturing, and commercialization. AI-enabled target discovery, molecular modeling, trial-site selection, and patient stratification can help sponsors identify responder profiles, optimize study design, and improve the probability of technical and regulatory success.

In commercialization and operations, AI supports demand planning, supply-chain visibility, adherence monitoring, pharmacovigilance, and real-world evidence generation. This is especially important for GLP-1 and incretin therapies, where high demand, complex biologics manufacturing, cold-chain logistics, and long-term persistence influence performance. Responsible deployment requires strong governance around data quality, privacy, bias mitigation, safety monitoring, and transparent clinical decision support.

Key Regional Insights

North America remains the most advanced commercial region for anti-obesity prescription drugs, led by the United States, where FDA-approved therapies, specialist prescribing, broad clinical awareness, and employer health-benefit debates are accelerating adoption. Canada is also seeing rising clinical interest, although reimbursement rules, formulary controls, and provincial access pathways shape the pace of use.

Europe is a highly evidence-driven region where the European Medicines Agency, national health technology assessment bodies, clinical guidelines, and payer negotiations influence the speed and breadth of uptake. Asia-Pacific carries major long-term treatment relevance because China, India, Japan, South Korea, Australia, and ASEAN economies face rising obesity, diabetes, and metabolic syndrome burdens, although affordability and reimbursement remain uneven. Latin America, led by Brazil and Mexico, is supported by high obesity prevalence and expanding private-sector demand. The Middle East, particularly Gulf countries, faces one of the world's highest cardiometabolic disease burdens, while Africa remains earlier in adoption, with access concentrated in urban private care and shaped by affordability, supply availability, cold-chain capacity, and competing public-health priorities.

Key Group Insights

G7 markets are setting the global direction for evidence standards, reimbursement debates, cardiovascular outcomes data, obesity clinical guidelines, and premium access expectations for anti-obesity prescription drugs. The European Union adds a centralized regulatory framework through regional authorization processes, but fragmented national access decisions make country-level health technology assessment, budget impact review, and payer negotiation essential for market entry.

BRICS countries represent the largest emerging demand pool because of population scale, urbanization, and increasing obesity-related diabetes, but affordability, local manufacturing policy, medicine availability, and public reimbursement constraints remain decisive. ASEAN markets show growing private-sector demand in urban centers as lifestyle-related metabolic disorders rise, while GCC countries are highly relevant due to elevated obesity and diabetes prevalence, high healthcare spending, and national prevention strategies. NATO countries overlap with many high-income pharmaceutical markets, where medicine security, supply resilience, cold-chain reliability, and cross-border regulatory alignment are becoming increasingly important for anti-obesity pharmacotherapy access.

Key Country Insights

The United States is the leading market for GLP-1 and dual incretin anti-obesity medicines, supported by FDA approvals, high clinical awareness, specialist and primary-care prescribing, and strong patient demand, but constrained by payer utilization management, coverage exclusions, prior authorization, and out-of-pocket costs. Canada is progressing through specialist-led adoption and guideline-driven care, while Mexico and Brazil combine high obesity prevalence with uneven reimbursement, expanding private demand, and growing recognition of obesity as a chronic disease requiring medical treatment.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national payer assessments, obesity service capacity, prescribing controls, and evidence of cost-effectiveness, while Russia remains more dependent on local access dynamics, regulatory pathways, and medicine availability. China and India offer major long-term treatment relevance because of large populations and rising metabolic disease, with affordability and access infrastructure remaining central considerations. Japan and South Korea emphasize regulated medical adoption, safety monitoring, and obesity-related comorbidity management, while Australia benefits from established obesity care pathways, specialist prescribing, and strong awareness of cardiometabolic risk reduction.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, sleep apnea, kidney outcomes, liver health, quality of life, safety, and treatment persistence data. Building payer-ready evidence packages is essential as health systems evaluate chronic therapy costs against long-term reductions in obesity-related complications.

Organizations should also invest in scalable manufacturing, supply-chain resilience, cold-chain quality, patient-support programs, adherence tools, and real-world evidence platforms. Competitive advantage will increasingly come from oral or less frequent dosing, improved tolerability, personalized treatment pathways, responsible AI use, and partnerships with employers, providers, pharmacies, and digital health platforms to improve persistence and measurable outcomes.

Research Methodology

The executive summary is based on a structured review of verified public-domain evidence, including regulatory approvals and prescribing labels from the FDA and EMA, clinical trial registries, peer-reviewed trial publications, World Health Organization obesity statistics, national public-health sources, treatment guidelines, and publicly disclosed clinical development updates.

The methodology emphasizes triangulation across epidemiology, regulatory status, clinical efficacy, safety, reimbursement dynamics, access conditions, and regional healthcare infrastructure. Insights were synthesized qualitatively to identify strategic implications for anti-obesity prescription drugs without relying on unverified market-size claims, market share statements, or unsupported forecasts.

Conclusion

Anti-obesity prescription drugs are entering a new phase defined by high-efficacy incretin therapies, expanding clinical evidence, and stronger recognition of obesity as a chronic disease requiring medical management. The category is no longer limited to weight reduction; it is increasingly linked to cardiometabolic risk management, comorbidity prevention, and long-term health-system value.

Future leadership will depend on proof of durable outcomes, equitable access, manufacturing reliability, payer engagement, responsible AI integration, and innovation that improves tolerability and convenience. Organizations that combine clinical rigor with responsible commercialization will be best positioned in the evolving global obesity pharmacotherapy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-obesity Prescription Drugs Market, by Drug Class

  • 7.1. GLP-1 Agonists
    • 7.1.1. Liraglutide
    • 7.1.2. Semaglutide
  • 7.2. Setmelanotide
  • 7.3. Orlistat
  • 7.4. Tirzepatide

8. Anti-obesity Prescription Drugs Market, by Dosage Form

  • 8.1. Injectables
  • 8.2. Orals
    • 8.2.1. Capsules
    • 8.2.2. Tablets

9. Anti-obesity Prescription Drugs Market, by Therapy Type

  • 9.1. Monotherapy
  • 9.2. Combination Therapy

10. Anti-obesity Prescription Drugs Market, by Application

  • 10.1. Core Obesity / Overweight Management
  • 10.2. Pediatric Obesity Management
  • 10.3. Precision-Obesity Applications

11. Anti-obesity Prescription Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics
    • 11.4.1. Endocrinology Clinics
    • 11.4.2. General Practice Clinics
    • 11.4.3. Weight Loss Clinics

12. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Anti-obesity Prescription Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Anti-obesity Prescription Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-obesity Prescription Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alizyme Limited
  • 17.2. Amgen Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. BioCon Limited
  • 17.5. Boehringer Ingelheim International GmbH
  • 17.6. CHEPLAPHARM Arzneimittel GmbH
  • 17.7. Currax Pharmaceuticals LLC
  • 17.8. Eli Lilly and Company
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. GlaxoSmithKline PLC
  • 17.11. Hangzhou Sciwind Biosciences Co., Ltd.
  • 17.12. Hanmi Pharm.Co., Ltd.
  • 17.13. HK inno.N Corporation
  • 17.14. Innovent Biologics, Inc.
  • 17.15. Merck & Co., Inc.
  • 17.16. Novo Nordisk A/S
  • 17.17. Orexigen Therapeutics, Inc.
  • 17.18. Pfizer Inc.
  • 17.19. Reddy's Laboratories Limited
  • 17.20. Rhythm Pharmaceuticals, Inc.
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Teva Pharmaceuticals Company Limited
  • 17.23. Verdiva Pharma Inc.
  • 17.24. Viking Therapeutics
  • 17.25. Vivus LLC
  • 17.26. Zealand Pharma A/S
  • 17.27. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIRAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIRAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIRAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEMAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEMAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEMAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SETMELANOTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SETMELANOTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SETMELANOTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORLISTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORLISTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORLISTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TIRZEPATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TIRZEPATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TIRZEPATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORE OBESITY / OVERWEIGHT MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PRECISION-OBESITY APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WEIGHT LOSS CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA ANTI-OBESITY PRES